section name header

Pronunciation

dye-peer-ID-a-mole

Classifications

Therapeutic Classification: antiplatelet agents, diagnostic agents (coronary vasodilators)

Pharmacologic Classification: platelet adhesion inhibitors

Indications

BEERS REMS


Action

  • PO: Decreases platelet aggregation by inhibiting the enzyme phosphodiesterase.
  • IV: Produces coronary vasodilation by inhibiting adenosine uptake.
Therapeutic effects:
  • PO: Inhibition of platelet aggregation and subsequent thromboembolic events.
  • IV: In diagnostic thallium imaging, dipyridamole dilates normal coronary arteries, reducing flow to vessels that are narrowed and causing abnormal thallium distribution.

Pharmacokinetics

Absorption: Moderately absorbed (30–60%) after oral administration. IV administration results in complete bioavailability.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Metabolized by the liver; excreted in the bile.

Half-Life: 10 hr.

Time/Action Profile

(PO = antiplatelet activity, IV = coronary vasodilation)

ROUTEONSETPEAKDURATION
POunknownunknownunknown
IVunknown6.5 min30 min



From start of infusion.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension, arrhythmias, flushing,

IV only

MI

GI: nausea, diarrhea, GI upset, vomiting

Derm: rash

Neuro: dizziness, headache, syncope,

IV only

transient cerebral ischemia, weakness

Resp:

IV only

bronchospasm

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Persantine

Canadian Brand Names

Persantine